• DOI:10.1128/AAC.46.6.1880-1886.2002
• Corpus ID: 20288140

Identification of a Series of Tricyclic Natural Products as Potent Broad-Spectrum Inhibitors of Metallo-β-Lactamases

@article{Payne2002IdentificationOA,
  title={Identification of a Series of Tricyclic Natural Products as Potent Broad-Spectrum Inhibitors of Metallo-$\beta$-Lactamases},
  author={David J. Payne and Juan A. Hueso-Rodr{\'i}guez and Helen F. Boyd and Nestor O. Concha and Cheryl A. Janson and Martin Gilpin and John H. Bateson and Christy Cheever and Nancy Niconovich and Stewart C. Pearson and Stephen F. Rittenhouse and David Tew and Emilio D{\'i}ez and Paloma P{\'e}rez and Jes{\'u}s Angel de la Fuente and Mike Rees and Alfonso Rivera-Sagredo},
  journal={Antimicrobial Agents and Chemotherapy},
  year={2002},
  volume={46},
  pages={1880 - 1886}
}

• D. Payne, J. Hueso-Rodríguez, +14 authors A. Rivera-Sagredo
• Published 1 June 2002
• Biology, Chemistry
• Antimicrobial Agents and Chemotherapy

ABSTRACT This work describes the discovery and characterization of a novel series of tricyclic natural product-derived metallo-β-lactamase inhibitors. Natural product screening of the Bacillus cereus II enzyme identified an extract from a strain of Chaetomium funicola with inhibitory activity against metallo-β-lactamases. SB236050, SB238569, and SB236049 were successfully extracted and purified from this extract. The most active of these compounds was SB238569, which possessed Ki values of 79, 17, and 3.4 μM for the Bacillus cereus II, Pseudomonas aeruginosa IMP-1, and Bacteroides fragilis CfiA metallo-β-lactamases, respectively, yet none of the compounds exhibited any inhibitory activity against the Stenotrophomonas maltophilia L-1 metallo-β-lactamase (50% inhibitory concentration > 1,000 μM). The lack of activity against angiotensin-converting enzyme and serine β-lactamases demonstrated the selective nature of these compounds. The crystal structure of SB236050 complexed in the active site of CfiA has been obtained to a resolution of 2.5 Å. SB236050 exhibits key polar interactions with Lys184, Asn193, and His162 and a stacking interaction with the indole ring of Trp49 in the flap, which is in the closed conformation over the active site groove. SB236050 and SB238569 also demonstrate good antibacterial synergy with meropenem. Eight micrograms of SB236050 per ml gave rise to an eightfold drop in the MIC of meropenem for two clinical isolates of B. fragilis producing CfiA, making these strains sensitive to meropenem (MIC ≤ 4 μg/ml). Consequently, this series of metallo-β-lactamase inhibitors exhibit the most promising antibacterial synergy activity so far observed against organisms producing metallo-β-lactamases.